Webinar
Foundations and implications for international reference pricing
International Reference Pricing (IRP) continues to shape pharmaceutical pricing strategies worldwide, with more than 75 countries leveraging this mechanism to benchmark drug costs and address affordability. In 2026, the landscape is shifting as reforms and initiatives, including the U.S. Most Favored Nation (MFN) model, challenge traditional IRP approaches. At the same time, trends such as confidential pricing agreements and evolving regulatory frameworks are creating ripple effects on global launch sequencing, access to medicines, and innovation. Watch the webinar recording for insights on how to navigate these changes and manage pricing complexity while balancing commercial sustainability with equitable access to life-saving treatments.
Key highlights
- Clarify how IRP reforms, including MFN-type models, are influencing global strategies.
- Examine real-world examples of IRP-driven pricing pressures.
- Identify tactics for launch sequencing, differential pricing, and value retention.
- Prepare for a future where transparency and confidentiality must coexist.
Moderator:
Chelsey Campbell, Senior Director, Commercial Excellence, Cencora
Speakers:
David Ringger, Director, Global Market Access & Pricing (GMAP), Cencora
Casper Paardekooper, VP, Head of Pricing, Policy & Stakeholder Engagement, Europe, Cencora
Access the recording to learn more and stay ahead in an evolving global healthcare environment
Pardot Form
